FIBRONEER-ON: Extension Trial for IPF

Trial Objectives

---

Continuous scarring (fibrosis) can gradually impair lung function, leading to breathing difficulties. Researchers are examining how an investigational medication called BI 1015550 can help adults with progressive lung diseases with fibrosis in a follow-up to the international FIBRONEER clinical trials.

Participants in this study will be given BI 1015550 whether or not they received the treatment or a placebo (a medication with no active ingredient) in the previous phases of the trial. All participants will receive lung function testing to determine what dose of the treatment is most effective for their symptoms. This data will help researchers determine how effective and safe this treatment is in a longer term than the original study.